Posted on 377
Tremeau Pharmaceuticals announced today that Gurnet Point Capital has agreed to fund the clinical development of its investigational drug TRM-201 (rofecoxib), including a Phase III trial of TRM-201 for hemophilic arthropathy (HA). Gurnet Point Capital, a private investment firm focused on the healthcare and life sciences sectors, is Tremeau’s primary investor.
HA is a painful and degenerative joint disease caused by recurrent intra-articular bleeding in patients with inheritable bleeding disorders. Although HA is the leading cause of morbidity in patients with hemophilia,
1 there currently are no medications in the United States indicated to treat joint pain in people with bleeding disorders